EMA OKs new measures to minimize jaw osteonecrosis with Aclasta
This article was originally published in Scrip
The European Medicines Agency has completed another review of the risk of osteonecrosis of the jaw with Novartis' bisphosphonate drug Aclasta (zoledronic acid) and has recommended that while the risk remains very low, a number of precautionary measures should be introduced, including updates to the product information and the launch of a patient reminder card.
You may also be interested in...
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.
The UK government has awarded “urgent public health status” to a clinical trial program that will test one investigational product and four existing drugs in an effort to quickly find new treatments for patients hospitalized with serious COVID-19 infection.